Zacks Investment Research has downgraded the shares of Radius Health (NASDAQ: RDUS) from an assessment to a sales evaluation in a research note published on Thursday.
According to Zacks, "Radius got a boost with the approval of the main drug Tymlos, Tymlos sales continue to gain ground, with total prescriptions accounting for 22% of the total market for anabolic osteoporosis in the United States ( based on Months Months Therapy, TRx PMOT) in the quarter Tymlos is expected to be covered for approximately 274 million lives insured, accounting for about 95% of the commercial USA and 64% of Medicare insured lives from 1 January 2019. However Radius was arrested when the CHMP reported a negative trend vote for the MAA following a re-examination of its top-flight drug Tymlos, followed by the CHMP saying it had maintained its negative opinion on the 39; AIC to its formal final vote While the postmenopausal osteoporosis market provides significant commercial potential, it is rather crowded given the presence of products such as Prolia di A mgen and Forteo di Lilly. The shares have underperformed the sector in the last six months. "
Many other equity research analysts have also published reports on the stock. Cowen reiterated a holding assessment of Radius Health's shares in a research note on Thursday 18 October. BidaskClub updated Radius Health's shares from a strong sales rating to a sales rating in a research note on Tuesday 2 October. JPMorgan Chase & Co. lowered their price target on Radius Health shares from $ 59.00 to $ 52.00 and set an overweight on the stock in a research note on Friday 2 November. Finally, ValuEngine lowered Radius Health's shares from a valuation to a sales valuation in a research note on Wednesday, January 2. Two research analysts rated the stock with a sales rating, four assigned a hold rating, and five assigned a rating to the company. The stock currently has a Hold consensus rating and an average price target of $ 44.50.
On Thursday, RDUS sold $ 0.50 during trading, reaching $ 16.44. The company had a trading volume of 523,800 shares, compared to its average volume of 729,037. The stock has a market capitalization of $ 755.50 million, a P / E ratio of -2.83 and a beta of 0.94. Radius Health has a minimum of one year of $ 12.81 and a maximum of one year of $ 41.16. The company has a current ratio of 5.50, a quick ratio of 5.39 and a debt / equity ratio of 1.85.
Radius Health (NASDAQ: RDUS) has published its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($ 1.09) EPS for the quarter, exceeding the consensus estimate of $ 1.26 for $ 0.17. The company recorded revenue of $ 27.7 million in the quarter, compared to analysts' expectations of $ 26.00 million. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. Revenues from the company rose by 105.2% compared to the same quarter last year. During the same period of the previous year, the company published ($ 1.31) EPS. On average, equity research analysts predict that Radius Health will post a -5.17 EPS for the current fiscal year.
In other news, the largest shareholder Growth N. V. Biotech has acquired 60,000 shares of the stock in a transaction dated Friday, December 14th. The shares were purchased at an average cost of $ 15.64 per share, for a total transaction of $ 938.400.00. Following the purchase, the insider now directly owns 6,650,276 shares of the company, for a value of $ 104,010,316.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, available on the SEC website. In addition, VP Joseph Francis Kelly acquired 3,000 shares of the stock in a transaction dated Monday, December 17. The shares were purchased at an average price of $ 15.71 per share, for a total transaction of $ 47.130.00. Following the completion of the purchase, the vice president now owns 3,000 shares of the company directly, worth $ 47,130. The disclosure for this purchase can be found here. Insiders have acquired a total of 123,000 company shares worth $ 1,854,330 in the last quarter. Employees own 3.32% of the company's shares.
Institutional investors have recently added or reduced their holdings in the company. Belpointe Asset Management LLC has acquired a new position in shares of Radius Health in the third quarter of the value of approximately $ 110,000. Cubist Systematic Strategies LLC increased its stake in Radius Health shares by 9,303.0% during the second quarter. Cubist Systematic Strategies LLC now owns 9,403 shares of the biopharmaceutical company's shares valued at $ 277,000 after the purchase of an additional 9,303 shares during the last quarter. Pacer Advisors Inc. acquired a new position in Radius Health shares in the third quarter of approximately $ 186,000. Verition Fund Management LLC acquired a new position in shares of Radius Health in the third quarter of approximately $ 208,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in shares of Radius Health in the third quarter of approximately $ 264,000.
About Radius Health
Radius Health, Inc., a biopharmaceutical company, develops and markets endocrine therapies in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing a transdermal patch of abaloparatide, a short-acting patch formulation of abaloparatide that is in a phase III clinical trial for the treatment of postmenopausal women with osteoporosis; RAD1901, a down-regulator / degradation of the selective estrogenic receptor, found in the Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a selective non-steroidal androgen receptor modulator that is in a Phase I clinical trial for breast cancer.
History in focus: market capitalization
Get a free copy of the Zacks research report on Radius Health (RDUS)
For more information on Zacks Investment Research research offers, visit Zacks.com
Get news and ratings for Radius Health Daily – Enter your email address below to receive a summary daily summary of the latest analyst news and ratings for Radius Health and companies associated with the FREE daily MarketBeat.com newsletter.